Antidepressants

A new study in JAMA reveals that, on average, 25% of beginning physicians meet the diagnostic criteria for major depression. In an accompanying editorial, Dr. Thomas Schwenk, added: "Everybody asks me, because of some of my prior studies, should we have more intense work in diagnosing depression in students? Of course, the answer is 'yes,' but how do you go about that without further stigmatizing them, further labeling them, further singling them out to even greater stigma? It's not just an issue of, 'Let's make better diagnoses and let's provide better treatment'; it’s more complicated than that."

A phase 1 study for a stem cell derived agent that promotes the growth of new nerve cells in the brain demonstrated efficacy in a very small sample of patients diagnosed with major depressive disorder (MDD). The phase 1B study was published online December 8 in Molecular Psychiatry.

A new study, published this week in BMJ, found no major differences in the effectiveness of cognitive behavioral therapy (CBT) and antidepressants. When the researchers compared previous studies, they found no major differences in relapse rates or level of treatment response between those taking antidepressants and those undergoing CBT.

The New York Times reports that a growing number of infants and toddlers are being prescribed dangerous psychiatric drugs. “Almost 20,000 prescriptions for risperidone (commonly known as Risperdal), quetiapine (Seroquel) and other antipsychotic medications were written in 2014 for children 2 and younger, a 50 percent jump from 13,000 just one year before.”

The Wall Street Journal highlights a new study that found that off-label medications represent about 12% of drug prescriptions and are resulting in negative...

Gepirone, a new depression drug by Fabre-Kramer Pharmaceuticals, did not meet the FDAs efficacy standards. The new drug application for gepirone has now received...

In 2004, the FDA added a black-box warning to SSRI antidepressants on the increased risk of suicide among children taking these drugs. A new study suggests that this warning has increased the proportion of children who begin an antidepressant on a low dose, but the majority are still receiving higher than recommended doses.

Acknowledging that current depression treatments are failing many people, researchers from Michigan State and MIT have developed a new model for understanding how multiple psychological, biological, social and environmental factors contribute to depression.

In a new study, researchers found that bright light therapy was an effective treatment for nonseasonal major depressive disorder (MDD) while Prozac (Fluoxetine) alone...

Ed Silverman reports that only 80 prescriptions for Addyi, or Flibanserin, were filled in the drugs’ first two weeks on the market. Article →

A “not otherwise specified” (NOS) diagnosis is often used when an individual may have some symptoms related to a psychiatric diagnosis but does not meet enough criteria to warrant a particular diagnosis. A new study, published online ahead of print in Psychiatric Services, reveals that the proportion of mental health visits resulting in such NOS diagnoses rose to nearly fifty percent, and that these diagnoses do not result in more conservative psychiatric drug prescriptions.

With the American Medical Association (AMA) declaring its opposition to direct-to-consumer (DTC) drug advertising, Martha Rosenberg asks, did DTC increase the number of people who have "diseases"?

More than ten-percent of adults in the United States are currently prescribed at least one psychiatric medication but there is currently a lack of research on the prevalence of adverse drug events (ADEs) associated with these prescriptions outside of clinical trials.

Infants exposed to SSRIs and benzodiazepines during pregnancy show impaired neurologic functioning in the first month after birth, according to a new study published in the American Journal of Psychiatry. While infants exposed SSRIs alone showed neurobehavioral effects throughout the first month, those exposed to an SSRI and a benzodiazepine had more significant problems.

“My vegetable beds have even buoyed me through more acute stressors, such as my medical internship, my daughter’s departure for college, and a loved one’s cancer treatment,” writes Dr. Daphne Miller. Now neuroscientists are attempting to study the antidepressant effects of soil microbes in hopes of unlocking the secrets of a powerful mood enhancer.

From 1999 to 2012 the percentage of Americans on antidepressants increased from 6.8% to 13%, according to a report published this week by the...

The German news agency DW features a video report on whether cannabidiol, an active substance derived from marijuana, can help relieve the symptoms of schizophrenia.

A new study on the depression symptoms of over three-thousand patients challenges the criteria used for diagnosing major depression with the latest Diagnostic and Statistical Manual (DSM-5). Current diagnostic systems are based on an assumption that the symptoms of depression point to a common underlying “illness," but research suggests that this framework may be outdated and oversimplified.

New research suggests that more frequent in-person contact lessens the risk of depression in older adults. The study, published in this month’s issue of the Journal of the American Geriatric Society, found that in Americans over fifty the more face-to-face contact they had with children, family and friends, the less likely they were to develop depressive symptoms.

At CounterPunch, Joseph Natoli connects Big Pharma, mass shootings, and rampant inequality. He writes: “The Brave New World soma strategy to deal with a population that, were they not doped up, might violently disrupt that brave new world, is useful if a society is ‘creatively destroying’ a growing number of its population each day. While the poor have daily evidence of their poverty, a collapsing middle class live in the illusion that they are middle class and just a short distance, not from ruin, but from fame and fortune. They are, in short, heading for a catastrophic break-down. Big Pharma is already set to give us all a ‘soft landing.’”

In a bellwether case, plaintiffs allege that Pfizer did not adequately warn patients that Zoloft (sertraline) would cause birth defects. The case is scheduled in Federal Court in March, and the verdict will have significant implications for future suits.

The UK Times reports that pharmaceutical companies are actively lobbying to limit the release of clinical trial data to the public. Rather than limiting results and data to medical journals, new transparency initiatives are pushing for making the information publically available. The push for transparency comes in the wake of the reanalysis of the Study 329 data on paroxetine (marketed as Seroxat and Paxil), which found that the industry study had misconstrued its results.

Results of a new study reveal that sixty-nine percent, or more than two-thirds, of patients prescribed antidepressant drugs have never, in their medical history, met the criteria for major depression. The study, published in the Journal of Clinical Psychiatry this month, also found that several demographic factors, like race and gender, were associated with the prescription of antidepressants.

This week the drug monitoring and patients' rights website, RxISK, launched the Centre for Medication Withdrawal, a page dedicated to establishing what causes dependence and how to treat it.

A massive number of meta-analyses of antidepressant clinical trials have financial conflicts of interest and are unduly influenced by pharmaceutical companies, according to a review to be published in an upcoming issue of the Journal of Clinical Epidemiology. Researchers also found that meta-analyses with industry ties almost never report any negative findings in their abstracts.